THE EFFECT OF MP-809 IN DEPRESSIVE STATES: A MULTI-BLIND STUDY
Abstract
1. A new substance, MP-809, a tryptamine derivative, was investigated in 50 depressed patients, as compared to two other groups of 50 depressed patients receiving inert and potent placebo, in a multiblind controlled setting.
2. Clinically MP-809 had a significant (marked to moderate) antidepressant activity in 52% of all patients and in 74.1% of neurotic depressions. Statistically the results were significantly in favour of MP-809 as compared with the two placebos, and this significance reached the high level of P<0.001 in neurotic depressions.
3. Side effects were frequent but minimal in their intensity.
4. The final conclusion was that MP-809 is a potent antidepressant agent particularly in neurotic depressive states.
Access content
To read the fulltext, please use one of the options below to sign in or purchase access.- Personal login
- Institutional Login
- Sign in via OpenAthens
- Register for access
-
Please login/register if you wish to pair your device and check access availability.
Not a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).
